A clinical trial consent form can land in your hands when your mind already feels full. You may be weighing cancer treatment, a possible remission, side effects, family needs, and the fear that comes with a life-threatening disease.
Reading the form is part of an ongoing informed consent process in clinical research, not a one-time signature. If the study involves an investigational drug, the form should explain its known risks and uncertainties. It doesn’t promise a benefit or remission. Read it slowly, mark what feels unclear, and discuss it with the research team, your oncology team, and a trusted support person. This article provides educational information, not medical or legal advice.
What a cancer clinical trial consent form is, and isn’t
An informed consent form is one part of the continuing informed consent process. It explains what a study asks of you and what researchers know so far. The National Cancer Institute’s definition of informed consent describes consent as receiving important information about possible risks and benefits, not signing once.
It isn’t a treatment recommendation written just for you, even if the study involves an investigational drug. It isn’t a contract, a guarantee of benefit, or a promise of remission. A trial may offer access to a new approach, but an investigational drug can have uncertain effects.
Signing doesn’t lock you in
You can decide not to join or take the form home. You can review it with an oncologist, pharmacist, caregiver, or trusted support person.
Signing means you agree to take part based on the information available at that time. It does not take away your right to leave the study later.
Consent continues after the first appointment
New information can change how you feel about participating. The study team must share important findings that could affect study participants’ decisions.
Ask who will contact you, how quickly they will call, and whether you will need to sign an updated form. You deserve time to think, even when treatment decisions feel urgent.
Start with the key information first
The revised Common Rule asks researchers to place a short, focused explanation of key information at the beginning of many consent forms. Requirements can vary by study. Read that part before you get lost in long paragraphs and medical terms.
When you read consent materials for clinical trials, look for the plainest answers first: What is this study testing? How does the investigational drug work? Why might I qualify? What happens if I say yes?
Name the choice in front of you
Some cancer studies compare a new approach with standard treatment, such as an investigational drug. Others test a different dose, a new combination, or a way to prevent side effects involving an investigational drug. Some ask for scans, blood samples, or quality-of-life surveys.
Find out whether the investigational drug replaces part of your usual care or sits alongside it. Ask for the study number, the treatment schedule, and the research coordinator’s direct contact information.
Put risks beside benefits and alternatives
A form should describe potential risks and benefits, along with alternatives to joining. Those alternatives may include standard care, another study, symptom-focused care, no study treatment, or, when relevant, an expanded access program.
An expanded access program is different from a clinical trial and may involve different eligibility, evidence, and consent considerations. A possible benefit is not a guarantee. A risk may be common, rare, serious, temporary, or not yet known. Ask what the team has seen in earlier studies involving the investigational drug, and what they still don’t know.
The question isn’t “Is this trial good?” The question is “Does this trial make sense for my health, my hopes, and the life I need to live during treatment?”
The essential parts of a clinical trial consent form
The form may look long because it has several jobs. It explains the research plan, documents your choice, and sets out your rights. An investigational drug may be part of that plan. The FDA lists core informed-consent elements in its guidance for investigators and review boards.
An institutional review board reviews participant protections, while clinical investigators conduct the study. Consent form templates can help organize information, but they can’t replace study-specific details.
Study purpose, visits, and procedures
Look for the study’s purpose, how long it lasts, and what happens at each visit. The form should identify research-only procedures and distinguish them from standard care.
It should explain whether an investigational drug replaces standard treatment, is added to it, or is being tested for dose, safety, or effectiveness. An investigational drug may also be compared with a placebo or another treatment.
Pay attention to extra blood draws, biopsies, scans, questionnaires, hospital visits, and follow-up after treatment ends. Some visits may involve an investigational drug, including monitoring before, during, or after treatment.
Ask which visits the study pays for and which ones may affect your own schedule or insurance. The form should explain whether an investigational drug creates additional travel, testing, or treatment costs.
Risks, costs, privacy, and contacts
The document should say what discomforts, harms, or adverse effects may occur. For an investigational drug, ask how common and serious its known or possible risks are.
It should also explain possible costs, care or compensation for research-related injury when applicable, privacy protections, and who may see your health information. An investigational drug may involve costs that differ from regular care.
A HIPAA authorization may permit specified people or organizations to use or disclose your health information. Read the confidentiality policy carefully, since privacy protections have limits. A second HIPAA authorization reference should clarify what data will be shared, for what purpose, and for how long. Ask whether the research team can access your medical records.
Use this quick guide while you read.
| Look for | Ask the study team |
|---|---|
| Treatment plan | “What investigational drug or procedure is experimental?” |
| Risks and side effects | “What adverse effects from the investigational drug need a same-day call or emergency care?” |
| Potential benefit | “What benefit is realistic from the investigational drug for someone in my situation?” |
| Other choices | “What are my options if I do not join or take the investigational drug?” |
| Time and travel | “How many visits, tests, and follow-up calls are required for the investigational drug?” |
| Contacts | “Who answers questions about the investigational drug after hours, weekends, and holidays, and who is the study sponsor?” |
If you take medicine for another condition, including Parkinson’s disease, bring a complete list. Include prescriptions, infusions, vitamins, herbs, creams, inhalers, and medicines you use only when needed. Don’t start supplements or change medicines without checking with both your oncology team and the research team.
Your right to say no, pause, or withdraw
Voluntary participation means you can ask questions, say no, pause, or leave without pressure or penalty. This remains true throughout the informed consent process. Signing a form doesn’t create a contract or guarantee a benefit, and it doesn’t remove your right to withdraw.
Leaving a study after you sign
You can stop participating at any time without losing benefits or facing a penalty. Before stopping an investigational drug, contact the research team so they can help create a safe plan and arrange follow-up care.
Ask what happens to the investigational drug after you stop. Find out whether a final safety visit is needed after stopping the investigational drug, what follow-up is recommended, and what alternative care remains available.
Stopping may not mean the team destroys information or specimens already collected. The form should explain what happens to existing data and whether future collection from your medical records can continue.
Questions that protect your daily life
Ask what would happen if side effects become too hard while taking the investigational drug, your cancer grows, or travel becomes impossible. Find out who decides whether you can continue treatment and what other care remains available.
Write down the answers. When fatigue, pain, or fear makes information difficult to process, involve your oncologist and a trusted person. They can help you remember what was said and what comes next.
Adult consent, parental permission, and child assent
Adults who can make their own decisions usually sign their own informed consent form. When a child joins cancer research, a parent or legal guardian may complete a parental permission form when required.
What parental permission covers
A parent or legal guardian receives information about the study, including any investigational drug, procedures, possible risks, possible benefits, and alternatives. They can ask questions, take time to decide, and decline participation.
The study team should use language that fits the family’s needs. Ask for an interpreter if English isn’t the language you understand best.
Why a child’s assent matters
When a child can understand enough to take part in the choice, the team should seek assent through a child assent form or an age-appropriate discussion. Parental permission doesn’t replace the child’s voice. Silence, fear, or a lack of objection isn’t affirmative agreement.
Children deserve honest, age-appropriate explanations. Families can request more than one conversation, additional time to decide, and a familiar support person nearby.
When consent forms must be posted publicly
This rule applies to certain federally supported or conducted trials, not every cancer study. Under the 2018 Requirements of the revised common rule, researchers must post one consent form approved by institutional review boards and used to enroll participants.
Where researchers post the form
The NIH permits posting on ClinicalTrials.gov or Regulations.gov. These federal websites may host an English version approved by the IRB.
Public posting doesn’t mean the document contains your name or personal health details. It isn’t a set of consent form templates or your personal form. It also doesn’t prove an investigational drug is safe or effective, and it isn’t personal medical or legal advice.
The 60-day timing rule
Researchers must post the form after recruitment closes and no later than 60 days after the last study visit required by the protocol. The HHS posting instructions explain that the requirement applies to covered trials initially approved on or after January 21, 2019.
FDA regulations apply separately to trials involving drugs, biologic products, or medical devices. A study can involve more than one framework, which is why research paperwork sometimes feels layered.
Key takeaways to bring to your next visit
Bring the form, a notebook, and a medication list to your oncology team. Review the form with someone you trust, and let the conversation be slow enough for real answers.
- Ask which part of the treatment is research and which part is standard care.
- Record the investigational drug name exactly as the team gives it to you.
- Write down the investigational drug dose schedule and timing.
- Ask which products or medications may interact with the investigational drug.
- Ask whom to call about symptoms from the investigational drug, including the after-hours number.
- Ask what happens if you withdraw, miss a visit, have adverse effects, need another treatment, or cannot travel.
- Keep your oncologist involved, even when the clinical trial team leads the study visits.
You don’t need to know every medical term. You need enough information to make a voluntary, informed choice.
Frequently asked questions
Can I take the consent form home before signing?
Yes. Ask for time to read it away from the clinic. You can discuss it with your oncologist, pharmacist, family member, or another trusted clinician before deciding.
Can I join a trial and later change my mind?
Yes. You may withdraw at any time. Before you stop, speak with the research team about safety, follow-up care, and what happens with information already collected. Confirm alternatives and withdrawal plans with your oncology team.
Is an expanded access program the same as a research study?
No. An expanded access program may provide an investigational drug outside a research study. It isn’t automatically safer or more effective. Eligibility, available evidence, monitoring, costs, and availability may differ in an expanded access program. Ask your oncology team what options fit your situation.
Does a clinical trial guarantee remission?
No. An investigational drug may help some people. Even when an investigational drug shows promise, it can’t be promised to control cancer or lead to remission. Clinical trials may have different goals and results.
Who should I call if I have a new symptom?
Use the number in the form to contact the study team about study-related concerns, including adverse effects and after-hours questions. For severe symptoms such as trouble breathing, chest pain, severe confusion, or uncontrolled bleeding, seek urgent medical help.
A signature should come after understanding
A consent form may hold frightening words, but it shouldn’t rush you into a choice. Read for practical details, including the purpose, standard care, research procedures, and treatment with an investigational drug. Then review potential risks, possible benefits, alternatives, costs, privacy, compensation when applicable, time required, and who you can call.
Your signature should follow understanding that participation is voluntary and that you can withdraw. An expanded access program may be a distinct alternative, so discuss it with your oncology and research teams. No investigational drug guarantees remission. Bring unresolved questions to your oncology team and a trusted support person. Informed consent means your voice remains part of your care, during active treatment, after remission, and through every decision that asks for courage. This article is educational, not medical or legal advice.
